HUMAN CELL DESIGN

Their core work

Human Cell Design (operating as Univercell Biosolutions) is a French biotech SME specializing in human cell production, particularly pancreatic beta cells. They supply standardized human cell products for drug discovery screening and regenerative medicine applications. Their core value lies in providing researchers and pharma companies with reliable, scalable human cell models — especially for diabetes and disc degeneration therapies — bridging the gap between laboratory cell biology and clinical-grade cell therapy.

What they specialise in

How they've shifted over time

In the early period (2015–2017), Human Cell Design focused on establishing its core beta cell technology for diabetes drug screening (BETASCREEN) and joined the large INNODIA consortium contributing cell expertise to T1D biomarker discovery and clinical sample networks. From 2017 onward, they diversified into regenerative medicine with MSC-based disc therapy (RESPINE) while deepening their diabetes involvement through INNODIA HARVEST, which expanded into microbiome, immunology, and master-protocol clinical trials. The trajectory shows a company moving from a single cell-product supplier toward a broader regenerative medicine and translational research partner.

They are expanding from a niche beta cell supplier into a versatile cell therapy and translational medicine partner, with growing involvement in clinical trial infrastructure and immunology.

How they like to work

Human Cell Design primarily operates as a specialist partner in large research consortia — 3 of their 4 projects are as participant, with 60 unique partners across 18 countries. They coordinated one smaller SME instrument project (BETASCREEN), suggesting they can lead focused commercial efforts but prefer contributing specialized cell expertise to bigger collaborative programs. Their broad partner network indicates they are well-connected and trusted as a reliable niche contributor rather than a consortium organizer.

With 60 unique consortium partners across 18 countries, Human Cell Design has a remarkably wide European network for a small biotech SME, largely built through the large INNODIA consortia. Their collaborative footprint spans most of Western and Northern Europe.

What sets them apart

Human Cell Design occupies a rare niche: they are one of very few companies that can supply standardized human pancreatic beta cells at scale for both research and therapeutic applications. This makes them a uniquely valuable partner for any consortium needing human cell models for diabetes, drug screening, or regenerative medicine. Their dual track record — commercial cell products (BETASCREEN) and clinical-grade cell therapy (RESPINE) — means they can bridge the lab-to-clinic gap that many academic partners cannot.

Highlights from their portfolio

• INNODIA
  Their largest funded project (EUR 373,878), a major European T1D consortium running 8 years — demonstrates sustained, trusted involvement in flagship diabetes research.
• BETASCREEN
  Their only coordinated project, an SME Instrument Phase 1 focused on commercializing their proprietary beta cell screening platform for pharma drug discovery.
• RESPINE
  Significant diversification into regenerative spine therapy using MSC injection, showing cell expertise applied beyond diabetes into musculoskeletal medicine.